Bringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI ® and SYFOVRE ®, while Apellis’ talent and expertise will accelerate Biogen’s entry ...

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

The MarketWatch News Department was not involved in the creation of this content. Exton, PA, March 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announces the release of its latest Market ...

Exton, PA, March 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announces the release of its latest Market Dynamix™:Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a ...

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...

ABSTRACT: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare cause of hemolytic anemia that can be exacerbated by pregnancy. This case report reflects on this condition. A pregnant 27-year-old female ...

Atropos Health, a real-world data company, announced a partnership with pharmaceutical giant Novartis to help identify individuals with the rare disease paroxysmal nocturnal hemoglobinuria (PNH) who ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare cause of hemolytic anemia that can be exacerbated by pregnancy. This case report reflects on this condition. A pregnant 27-year-old female, a known ...

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups. Biosimilar SB12 ...

MONTREAL, April 14, 2025 /CNW/ - Novartis Canada is pleased to announce that Fabhalta ® (iptacopan capsules) is now available across Canada for adult patients with paroxysmal nocturnal hemoglobinuria ...